Skip to main
AXGN
AXGN logo

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc has demonstrated a positive financial trajectory, marked by a compound annual growth rate (CAGR) of 13.6% in revenue since 2020, reflecting strong market demand for its peripheral nerve repair technologies. The company benefits from increasing reimbursement rates, with the physician fee schedule for allograft procedures rising to $876 in 2025, a 9% increase since 2019, alongside a substantial 138% rise in average reimbursement for these procedures in ambulatory surgery centers, now averaging $4,565. This combination of consistent revenue growth and improving reimbursement dynamics positions Axogen favorably within the healthcare market, enhancing its potential for long-term success.

Bears say

Axogen Inc faces significant risks that could adversely impact its sales growth, including competitive pressures, regulatory challenges, and technological obsolescence, which may result in lower-than-expected revenue. Additionally, the company's reliance on securing regulatory approval for its flagship product, Avance, as a biologic presents a crucial hurdle alongside its historical net losses and dependency on key management for success. Furthermore, operational challenges such as difficulties in scaling production, maintaining quality, and addressing supply chain constraints could further undermine Axogen's ability to achieve sustainable profitability and expand its market presence.

AxoGen (AXGN) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Strong Buy based on their latest research and market trends.

According to 5 analysts, AxoGen (AXGN) has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.